Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Ferrer, Ricard
• dc.contributor.author Mateu de Antonio, Francisco Javier
• dc.contributor.author Maseda, Emilio
• dc.contributor.author Yébenes, Juan Carlos
• dc.contributor.author Aldecoa, César
• dc.contributor.author Haro, Candelaria de
• dc.contributor.author Ruiz-Rodríguez, Juan C.
• dc.contributor.author Garnacho Montero, José
• dc.date.accessioned 2018-11-09T08:30:06Z
• dc.date.available 2018-11-09T08:30:06Z
• dc.date.issued 2018
• dc.description.abstract Effective resuscitation with human albumin solutions is achieved with less fluid than with crystalloid solutions. However, the role of albumin in today's critical care unit is also linked to its multiple pharmacological effects. Areas covered: The potential clinical benefits of albumin in select populations of critically ill patients like sepsis seem related to immunomodulatory and anti-inflammatory effects, antibiotic transportation and endothelial stabilization. Albumin transports many drugs used in critically ill patients. Such binding to albumin is frequently lessened in critically ill patients with hypoalbuminemia. These changes could result in sub-optimal treatment. Albumin has immunomodulatory capacity by binding several bacterial products. Albumin also influences vascular integrity, contributing to the maintenance of the normal capillary permeability. Moreover, the albumin molecule encompasses several antioxidant properties, thereby significantly reducing re-oxygenation injury, which is especially important in sepsis. In fact, most studies of albumin administration are a combination of a degree of resuscitation with a degree of maintenance or supplementation of albumin. Expert commentary: The potential clinical benefits of the use of albumin in selected critically ill patients such as sepsis seem related to its immunomodulatory and anti-inflammatory effects, antioxidant properties, antibiotic transportation and endothelial stabilization. Additional studies are warranted to further elucidate the underlying physiologic and molecular rationale.
• dc.format.mimetype application/pdf
• dc.identifier.citation Ferrer R, Mateu X, Maseda E, Yébenes JC, Aldecoa C, De Haro C. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev Clin Pharmacol. 2018 Feb;11(2):125-137. DOI: 10.1080/17512433.2018.1412827
• dc.identifier.doi http://dx.doi.org/10.1080/17512433.2018.1412827
• dc.identifier.issn 1751-2433
• dc.identifier.uri http://hdl.handle.net/10230/35723
• dc.language.iso eng
• dc.publisher Taylor & Francis (Routledge)
• dc.relation.ispartof Expert Review of Clinical Pharmacology. 2018 Feb;11(2):125-37
• dc.rights © Taylor & Francis. This is an electronic version of an article published in Ferrer R, Mateu X, Maseda E, Yébenes JC, Aldecoa C, De Haro C. et al. Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients. Expert Rev Clin Pharmacol. 2018 Feb;11(2):125-137. Expert review of clinical pharmacology is available online at: https://www.tandfonline.com/doi/abs/10.1080/17512433.2018.1412827?journalCode=ierj20
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Albumin
• dc.subject.keyword Antioxidation
• dc.subject.keyword Critical care
• dc.subject.keyword Drug transportation
• dc.subject.keyword Endothelium
• dc.subject.keyword Immunomodulation
• dc.subject.keyword Sepsis
• dc.subject.other Albúmina
• dc.subject.other Antioxidants
• dc.title Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion